JNJ in-licenses BAYG thrombosis compound

Johnson & Johnson (JNJ) and Bayer (FSE:BAYG; BAY) partnered to co-develop and co-commercialize BAYG's BAY 59-7939 to prevent and treat thrombosis. The Factor Xa inhibitor is in Phase IIb trials to prevent venous thromboembolism after major orthopedic surgery, to treat venous thromboembolism and to prevent stroke in atrial fibrillation. BAYG plans to start a Phase III trial in the orthopedic surgery indication in the next few weeks. ...